FDA’s proposal to withdraw conjugated estrogens ANDAs
In a May 11 letter to FDA, Zenith asks for data and information relied upon in FDA's Feb. 13 notice of opportunity for a hearing proposing to withdraw the ANDAs. Zenith's requests include the plasma studies submitted by several generic companies seeking "AB" ratings for its conjugated estrogens, the "pharmacokinetic model developed by Wyeth-Ayerst to predict that the rate of absorption of all estrogen sulfates contributes to the proportion of active moeties in the plasma," and the data filed by Wyeth-Ayerst to support the effectiveness of its Premarin (innovator conjugated estrogens) tablets for osteoporosis.
You may also be interested in...
More than half a dozen generic rivaroxaban brands are now available in India, putting the heat on Bayer’s blockbuster anticoagulant Xarelto in the price-sensitive market. Many rival generics are priced over 50% lower than the innovator product.
In this week’s podcast, Medtech Insight's managing editor Marion Webb and deputy editor Reed Miller discuss highlights from the recent J.P. Morgan Healthcare and North American Neuromodulation Society (NANS) virtual meetings. London, UK-based reporter Barnaby Pickering profiles start-up CorWave SA, which developed a left ventricular assist device for treating end-stage heart failure.
Tom McLain tells how the new MCIT policy from the US Medicare agency – and winning support from Congress – will guarantee Medicare coverage for his company’s product, an artificial intelligence-enabled in vitro diagnostic platform.